{"analyses":[{"ciLowerLimit":"45.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"60.90","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Percent Difference","paramValue":"53.4","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8"},{"groupId":"OG001","value":"75.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"241"}],"units":"Participants"}],"description":"The ACR 20 response is defined as greater than or equal to (\\>=) 20 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints) and \\>=20% improvement from baseline in at least 3 of the following 5 assessments: Patient's assessment of pain (on a 0 to 10 centimeter \\[cm\\] scale), Patient's Global Assessment of Disease Activity (on a 0 to 10 cm scale), Physician's Global Assessment of Disease Activity (on a 0 to 10 cm scale), Patient's assessment of physical function as measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI) and measurement of a blood test called C-reactive protein (CRP).","groups":[{"description":"Participants received intravenous infusions of placebo at Weeks 0, 4, 12 and 20.","id":"OG000","title":"Placebo"},{"description":"Participants were randomized to receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants received a placebo infusion to maintain the blind.","id":"OG001","title":"Golimumab"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"Week 14","title":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}